SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-21-005265
Filing Date
2021-02-17
Accepted
2021-02-17 17:28:08
Documents
2
Group Members
GEORGE R. ROBERTSHENRY R. KRAVISKKR & CO. INC.KKR GENETIC DISORDER GP LLCKKR GROUP HOLDINGS CORP.KKR GROUP PARTNERSHIP L.P.KKR MANAGEMENT LLP

Document Format Files

Seq Description Document Type Size
1 SC 13D/A brhc10020517_sc13da.htm SC 13D/A 272124
2 EXHIBIT 99.H brhc10020517_ex99-h.htm EX-99.H 30990
  Complete submission text file 0001140361-21-005265.txt   305028
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Subject) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91059 | Film No.: 21646351
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Business Address C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 (212) 750-8300
KKR Genetic Disorder L.P. (Filed by) CIK: 0001780408 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A